GoodRx (GDRX) stock-based compensation was $77M in FY2025 (-23% YoY). The tables below show the complete quarterly and annual stock-based compensation history, sourced from SEC EDGAR 10-K and 10-Q filings.
Annual Stock-Based Compensation
Fiscal Year
Stock-Based Compensation
YoY
2025
$77M
-23%
2024
$99M
-6%
2023
$105M
-13%
2022
$120M
-25%
2021
$160M
-60%
2020
$397M
+10503%
2019
$4M
+113%
2018
$2M
Recent Quarterly Stock-Based Compensation
Quarter
Stock-Based Compensation
Q2 2026
$17M
Q1 2026
$17M
Q4 2025
$18M
Q3 2025
$18M
Q2 2025
$21M
Q1 2025
$19M
Q4 2024
$21M
Q3 2024
$26M
Q2 2024
$27M
Q1 2024
$25M
Q4 2023
$29M
Q3 2023
$33M
Source: GDRX on EDGAR. Data from SEC EDGAR 10-K and 10-Q filings. Updated quarterly.